Exhibit 99.1
|
|
|
|
|
Regulated Information
Inside Information |
Celyad announces management change
December 1st 2023, Mont-Saint-Guibert, BelgiumCelyad Oncology (Euronext:
CYAD), a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells announces that its CEO and managing
director Georges Rawadi has decided to step down, effective as of Friday December 1, 2023.
Georges has taken this decision for personal reasons.
Michel Lussier will take over the CEO responsibilities ad interim. Michel is co-founder and member of the board of Directors of Celyad Oncology.
Hilde Windels, Chair of Celyad Oncology, commented: We thank Georges for his efforts and dedication to make this pivotal year a success, following
Celyads change in strategy since last year. We wish him every success in the future.
The companys primary objective is to unlock the
potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. By fully leveraging its innovative technology
platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell therapies and redefine the future of CAR T-cell treatments.
Michel Lussier, interim CEO, commented: We are grateful for the work that Georges has done and I look forward to working closer with the team again in
this interim period. I am confident about the companys future: the science is great, we have cash in the bank and we have been very successful in our efforts to address the limitations of CAR-T. Hence,
we are ready to engage in value adding partnering discussions.
About Celyad Oncology
Celyad Oncology is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The Company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T
candidates in solid tumors and hematological malignancies. Celyad Oncology is based in Mont-Saint-Guibert, Belgium and New York, NY. For more information, please visit www.celyad.com.
Celyad Oncology Forward-Looking Statement
This release
may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding beliefs about and expectations
for the Companys updated strategic business model, including associated costs, cost savings and timing. The words will, expect, believe, potential, continue, target and
similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this release are based on managements current expectations
and beliefs and are subject to a number of known and unknown risks, uncertainties and important factors which might cause actual events, results, financial condition, performance or achievements of Celyad Oncology to differ materially from those
expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks related to the material uncertainty about the Companys ability to continue as a going concern; the
Page 1 of 2